Proactive - Interviews for investors
Just the Facts: Prescient Therapeutics secures FDA approval for PTX-100 Phase 2 trials
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF).
The company has received US FDA clearance to proceed with Phase 2 clinical trials for its Ras pathway inhibitor, PTX-100.
This study will focus on relapsed and refractory cutaneous T-cell lymphomas (r/r CTCL).
The decision follows the completion of a Phase 1b trial involving 19 T-cell lymphoma patients, which demonstrated an excellent safety profile and a 42% overall response rate.
Among evaluable r/r CTCL patients, five of seven experienced clinical benefits.
The global Phase 2 trial will enrol 115 patients across 15 sites in Australia, the US and Europe.
It will consist of two parts: dose optimisation and efficacy assessments. Primary endpoints include objective response rate, with secondary metrics focusing on progression-free survival, overall survival, safety, and quality of life.
The company describes FDA clearance as a transformative milestone, reflecting years of preclinical and clinical development.
Prescient aims to collaborate with global CTCL experts to deliver a safe and effective therapy for this area of unmet need. The announcement drove a 55% surge in the company’s shares.
#ProactiveInvestors #PrescientTherapeutics #ASX #OTC #PTX100 #FDAApproval #ClinicalTrials #OncologyResearch #TCellLymphoma #CTCL #CancerTreatment #OrphanDrug #Phase2Trial #GlobalTrial #DrugDevelopment #MedicalInnovation #PatientCare #RasPathway #CutaneousLymphoma #BiotechNews #ClinicalResearch #ASXStocks #PharmaInnovation
- Broadcast on
- 22 Dec 2024
This episode appears to contain dynamically inserted ads. Transcript timestamps may be approximate.
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF).
The company has received US FDA clearance to proceed with Phase 2 clinical trials for its Ras pathway inhibitor, PTX-100.
This study will focus on relapsed and refractory cutaneous T-cell lymphomas (r/r CTCL).
The decision follows the completion of a Phase 1b trial involving 19 T-cell lymphoma patients, which demonstrated an excellent safety profile and a 42% overall response rate.
Among evaluable r/r CTCL patients, five of seven experienced clinical benefits.
The global Phase 2 trial will enrol 115 patients across 15 sites in Australia, the US and Europe.
It will consist of two parts: dose optimisation and efficacy assessments. Primary endpoints include objective response rate, with secondary metrics focusing on progression-free survival, overall survival, safety, and quality of life.
The company describes FDA clearance as a transformative milestone, reflecting years of preclinical and clinical development.
Prescient aims to collaborate with global CTCL experts to deliver a safe and effective therapy for this area of unmet need. The announcement drove a 55% surge in the company’s shares.
#ProactiveInvestors #PrescientTherapeutics #ASX #OTC #PTX100 #FDAApproval #ClinicalTrials #OncologyResearch #TCellLymphoma #CTCL #CancerTreatment #OrphanDrug #Phase2Trial #GlobalTrial #DrugDevelopment #MedicalInnovation #PatientCare #RasPathway #CutaneousLymphoma #BiotechNews #ClinicalResearch #ASXStocks #PharmaInnovation